AUCTORES
Globalize your Research

New Medical Innovations and Research

Elizaveta I Bon *

Open Access

Short Communication

Novel Therapeutic Approaches for Oral Submucous Fibrosis

Ashish Pandey*, Haripriya Katira, Sneha Upadhyay, Anurag Tiwari, Rakshita Sen

Daswani Dental College affiliated to Rajasthan University of Health Sciences, India.

***Corresponding Author:** Ashish Pandey, Daswani Dental College affiliated to Rajasthan University of Health Sciences, India.

Received date: February 07, 2025; Accepted date: February 10, 2025; Published date: February 15, 2025

Citation: Ashish Pandey, Haripriya Katira, Dr Sneha Upadhyay, Anurag Tiwari, Rakshita Sen, (2025), Novel Therapeutic Approaches for Oral Submucous Fibrosis, *J New Medical Innovations and Research*, 6(2); **DOI:10.31579/2767-7370/143**

Abstract:

Oral Submucous Fibrosis (OSF) is a chronic, progressive, and potentially malignant disorder primarily associated with areca nut chewing. It results in fibrosis of the oral mucosa, leading to restricted mouth opening and a high risk of malignant transformation into oral squamous cell carcinoma. Conventional treatments, including steroids, antioxidants, and surgical interventions, have limited success in halting disease progression. This article explores novel therapeutic approaches such as molecular inhibitors, regenerative medicine, gene therapy, nanotechnology-based drug delivery, and immunomodulatory interventions. These emerging therapies offer promising avenues for improving patient outcomes by targeting the disease at a molecular and cellular level.

Keywords: oral submucous fibrosis; novel therapy; molecular targets; regenerative medicine; gene therapy; nanotechnology immunomodulation

Introduction

Oral Submucous Fibrosis (OSF) is a progressive, potentially malignant disorder predominantly affecting populations with habitual areca nut consumption [1]. The condition is characterized by excessive collagen deposition, leading to mucosal stiffness, pain, and progressive trismus [2]. Despite various therapeutic strategies, OSF remains a challenging condition due to its irreversible fibrotic changes and high risk of malignant transformation (7-13%) [3]. Emerging therapeutic approaches focus on halting fibrosis, reversing tissue damage, and preventing malignant progression.

Pathogenesis of OSF

The pathogenesis of OSF is multifactorial, involving genetic, environmental, and immunological factors. Areca nut constituents such as arecoline stimulate fibroblast proliferation and collagen synthesis, leading to an imbalance between collagen production and degradation [4]. Pro-inflammatory cytokines, including transforming growth factor-beta (TGF-β) and connective tissue growth factor (CTGF), further drive fibrosis [5]. Oxidative stress and epithelial atrophy contribute to malignant transformation [6]. Understanding these mechanisms has led to the development of novel therapeutic strategies.

Novel Therapeutic Approaches

Molecular Targeted Therapies

Advancements in molecular biology have identified key pathways involved in OSF pathogenesis, allowing for targeted therapies:

* TGF-β Inhibitors

TGF-β is a major driver of fibrosis in OSF. Small-molecule inhibitors such as SB-431542 and pirfenidone have shown potential in downregulating fibroblast activation and collagen synthesis [7]. Clinical trials evaluating TGF-β inhibitors in OSF are ongoing.

* Matrix Metalloproteinase (MMP) Modulators

MMPs play a crucial role in collagen degradation. MMP-9 activators and TIMP-1 inhibitors can potentially restore collagen homeostasis in OSF patients [8].

* Epigenetic Modulators

Histone deacetylase (HDAC) inhibitors, such as valproic acid, have demonstrated the ability to suppress fibroblast proliferation and induce apoptosis in preclinical OSF models [9].

Regenerative Medicine and Stem Cell Therapy

Regenerative approaches aim to reverse fibrosis and restore oral function:

* Mesenchymal Stem Cells (MSCs)

Bone marrow-derived MSCs have demonstrated antifibrotic properties by modulating immune responses and promoting collagen degradation [10]. A recent pilot study showed improvement in mouth opening and mucosal elasticity following MSC transplantation [11].

* Platelet-Rich Plasma (PRP) Therapy

PRP contains growth factors that promote angiogenesis and collagen remodeling. Studies have reported symptomatic relief and improved mouth opening in OSF patients treated with PRP injections [12].

Gene Therapy

Gene therapy presents a cutting-edge approach to OSF treatment:

* Anti-Fibrotic Gene Silencing

RNA interference (RNAi) techniques targeting TGF-β1 and CTGF genes have demonstrated fibrosis reversal in animal models [13].

* CRISPR-Cas9 Technology

CRISPR-based editing of pro-fibrotic genes is under investigation as a potential curative approach for OSF [14].

Nanotechnology-Based Drug Delivery

Nanotechnology enhances drug bioavailability and targeted delivery:

* Liposomal Drug Delivery Systems

Encapsulation of antifibrotic drugs (e.g., pirfenidone) in liposomal carriers has shown increased efficacy in preclinical OSF models [15].

* Nanoparticle-Based Antioxidants

Curcumin and resveratrol-loaded nanoparticles have demonstrated superior antifibrotic and antioxidant effects compared to conventional formulations [16].

Immunomodulatory Therapies

Dysregulated immune responses play a role in OSF pathogenesis. Immunomodulatory approaches include:

* JAK-STAT Pathway Inhibitors

Janus kinase (JAK) inhibitors, such as ruxolitinib, have been explored for their antifibrotic and anti-inflammatory effects in OSF [17].

* Anti-IL-6 Monoclonal Antibodies

Tocilizumab, an IL-6 inhibitor, has demonstrated efficacy in reducing inflammation and fibrosis in autoimmune diseases, and its potential use in OSF is under investigation [18].

Conclusion

OSF remains a significant public health challenge due to its progressive fibrosis and high risk of malignant transformation. While conventional treatments provide symptomatic relief, novel therapeutic strategies focusing on molecular pathways, regenerative medicine, gene therapy, nanotechnology, and immunomodulation offer promising avenues for effective management. Further clinical trials are needed to validate these emerging therapies and integrate them into routine clinical practice.

References

1. Tilakaratne WM, Klinikowski MF, Saku T, Peters TJ, Warnakulasuriya S. (2006). Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol. 42(6):561-568.
2. Gupta MK, Sharma P, Saraswat N. (2022). Emerging trends in the management of oral submucous fibrosis. J Oral Maxillofac Surg. 80(5):899-910.
3. Arakeri G, Patil SG, Aljabab AS, Lin KC, Merkx MA, Brennan PA. (2022). Oral submucous fibrosis: an update on pathogenesis and novel therapies. J Oral Pathol Med. 51(3):223-235.
4. Kumar S, Debnath N, Ismail MB, et al. (2019). Areca nut and its role in oral submucous fibrosis. Oral Oncol. 97:36-42.
5. Yang SF, Wang YH, Su NY, Yu HC, Wei CY, Yu CH. (2019). Effects of arecoline on TGF-β1 expression and collagen synthesis in fibroblasts derived from different oral tissues. J Formos Med Assoc. 118(4):901-910.
6. Kumar N, Rajput J, Srivastava M. (2021). Oxidative stress and oral submucous fibrosis: therapeutic implications. Oral Dis. 27(1):23-32.
7. Chen PH, Lee KW, Hsu CC. (2023). TGF-β inhibitors as potential antifibrotic therapy for OSF. Int J Mol Sci. 24(4):998.
8. Joshi SG, Babu S, Shetty B. (2022). Role of matrix metalloproteinases in OSF pathogenesis. Oral Pathol Med. 51(5):345-356.
9. Liu C, Sun L, Zhou R. (2021). Epigenetic modulation in OSF treatment: potential of HDAC inhibitors. J Oral Biosci. 63(4):287-295.
10. Wang Z, Yan X, Lin Y, et al. (2022). Mesenchymal stem cell therapy in oral submucous fibrosis: potential applications and challenges. Stem Cells Int. 2022:4568901.
11. Sharma S, Gupta P, Mishra R. (2023). Bone marrow-derived mesenchymal stem cells in treating oral submucous fibrosis: a pilot study. J Clin Exp Dent. 15(2):e101-108.
12. Jain A, Shetty DC, Kumar V. (2022). Role of platelet-rich plasma in the management of oral submucous fibrosis: a systematic review. J Craniofac Surg. 33(3):615-621.
13. Gupta S, Saxena P, Sen S, Kumar S. (2021). RNA interference in oral submucous fibrosis: a novel therapeutic perspective. J Gene Med. 23(7):e3345.
14. Alam S, Fatima N, Sarin A. (2022). CRISPR/Cas9 gene editing in oral potentially malignant disorders: future directions. Mol Ther Oncolytics. 24:236-245.
15. Mishra A, Khanna V, Verma R. (2023). Liposomal encapsulation of antifibrotic drugs for targeted therapy in oral submucous fibrosis. Biomed Pharmacother. 157:114005.
16. Prasad M, Patil S, Deshmukh V. (2022). Curcumin-loaded nanoparticles as a novel treatment for oral submucous fibrosis. J Oral Maxillofac Surg Med Pathol. 34(4):556-563.
17. Kumar R, Reddy K, Srinivas K. (2022). JAK-STAT pathway inhibition: a new therapeutic strategy for oral submucous fibrosis. J Oral Sci. 64(1):1-9.
18. Singh P, Agarwal N, Pandey R. (2023). Tocilizumab in the treatment of OSF: a new frontier in immunomodulation. Oral Dis. 29(2):101-110.
19. Nandini DB, Hegde S, Hegde U. (2022). Novel strategies for the prevention and management of oral submucous fibrosis: a review. Indian J Dent Res. 33(1):56-63.
20. Kumar A, Bhattacharya P, Sahoo N. (2023). Advances in drug delivery systems for the treatment of oral submucous fibrosis. J Adv Pharm Technol Res. 14(3):105-112.

DOI:10.31579/2767-7370/143